Equities

Relevium Technologies Inc

RLV.H:NEX

Relevium Technologies Inc

Actions
  • Price (CAD)0.02
  • Today's Change0.00 / 0.00%
  • Shares traded-1.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Feb 14 2022.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Relevium Technologies Inc. is a Canada-based company, which operates in the health and wellness industry with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operations of brands and businesses in the health and wellness markets with a focus on e-commerce. The Company operates through two wholly owned subsidiaries, BGX E-Health LLC and Biocannabix Health Corporation Inc. BGX E-Health LLC markets dietary supplements, nutraceuticals, sports nutrition, and cosmeceuticals, primarily through its Bioganix brand portfolio online in the United States. It provides a Push & Pull System by Bioganix. Push & Pull System is a comprehensive natural anti-aging system for complete skin care that combines collagen protein supplements (PUSH) and naturally sourced aloe vera skin anti-aging cream (PULL).

  • Revenue in CAD (TTM)14.25m
  • Net income in CAD-2.64m
  • Incorporated2012
  • Employees--
  • Location
    Relevium Technologies Inc1000 Sherbrooke St W Suite 2700MONTREAL H3A 3G4CanadaCAN
  • Phone+1 (514) 824-8559
  • Fax+1 (514) 824-8559
  • Websitehttps://releviumtechnologies.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
EastWest Bioscience Inc789.84k108.55k2.50m------23.993.170.00080.00080.0080.03410.1471.277.11---0.0108---0.0315--66.74---0.0734--0.0281-3.130.4175---19.03---41.80------
ORAGIN Foods Inc23.25m-3.17m3.14m125.00------0.1352-0.0519-0.05190.38060.18730.904311.97200.90185,973.30-12.32-15.01-14.64-19.6929.8528.90-13.62-9.390.226-1.450.485---15.0840.76-1,034.28--1.44--
Relevium Technologies Inc14.25m-2.64m6.64m--------0.4663-0.0158-0.01580.052-0.00350.9457153.6713.51---17.50-72.98---132.3317.32---18.50-184.280.58561.744.40---69.28--22.55------
DavidsTea Inc60.64m-13.83m7.85m159.00--0.3683--0.1295-0.5171-0.51712.270.80111.142.0623.98---26.01-8.47-39.58-16.7540.1844.74-22.80-6.661.25--0.2874---26.96-22.207.00---23.58--
Data as of Feb 14 2022. Currency figures normalised to Relevium Technologies Inc's reporting currency: Canadian Dollar CAD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.